Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma

NCT01007149 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

79

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: omalizumab
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals